about
Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cellsGlutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation.Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.Unrelated donor transplantation for acute myelogenous leukemia in first remissionBusulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamideThe synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodelingInterstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipientsGlutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning.High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphomaDetection of busulfan adducts on proteins.Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and muTherapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher MiceHumanizing NOD/SCID/IL-2Rγnull (NSG) mice using busulfan and retro-orbital injection of umbilical cord blood-derived CD34(+) cells.Quantification of human plasma-busulfan concentration by liquid chromatography-tandem mass spectrometry.Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation.Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies.Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?Personalizing chemotherapy dosing using pharmacological methods.Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.Reduction of Leukocyte Counts by Hydroxyurea Improves Cardiac Function in Rats with Acute Myocardial InfarctionMini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.Impact of Oral and Gastrointestinal Mucositis on Body Weight Alterations during Hematopoietic Stem Cell Transplantation.A novel drug interaction between busulfan and blinatumomab.Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation.Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission.
P2860
Q28080914-F9DCA615-A3E2-450D-B32B-E7D80CD185EBQ28395254-9DF9B8BC-9B3F-4245-8F4F-F0102261872DQ33558113-D489AD02-D685-47E2-ACAF-C6946093CC53Q33652742-9D756B20-4FDE-4F06-ABAD-E8F6B59C98E6Q33665187-9E3E8A6C-FB85-4CDD-9A77-96FBCDE7F660Q33841417-BB3A8B72-D541-4A69-8A7B-49A47EA64A82Q34255145-A10EDAE2-CBB3-4378-AAF1-257E43D32D22Q34316871-E62BAF63-F6B6-443E-BA07-960B13842BFCQ34425136-C2B7D342-E50A-4659-BB9D-3B9EC3C138F8Q35136616-4C72C918-F25D-480D-88CD-0E1878ED2F3CQ35177432-8DBCEC60-D546-49B9-AD3B-3BDE3A433B7CQ35760706-1DFAB63A-D4B4-46C8-B646-AFE9C52655C3Q35861851-6518D6AB-2A0B-4B89-A39D-2634BE6AC486Q36036179-E64E8D26-2320-47D8-BEF4-C914FAF807EAQ36124146-B0619BCC-B21B-4DD5-A3C4-9F7D805C3B17Q36220882-FE3CD655-608D-4399-A05B-096D13524416Q36608468-3C78C09C-EE04-46B3-BC8A-54FACC9C16C4Q36703516-7A4FEEDF-997B-4EE2-9294-3E777628B53BQ36757186-AEFA25C0-1E23-444B-A01B-06FD5ED53D0AQ36789424-1161BB66-1F82-4732-86AC-4BF2C313277BQ37453495-19361E4E-D2F9-4FCC-BF54-F7475A8638D0Q38060264-FCA33CED-28C1-4B0F-96C8-B6E4BB5FD7A2Q38068541-5217077E-0179-4810-AB70-53E3A798488DQ38095526-3A775B57-4C2B-4801-B53F-AEF6C3D20CFCQ38095833-A871A650-31F7-46F4-BB69-E95F296937C1Q38225489-9C854D1C-0086-4DE5-8F6B-6B3FA36719ADQ38571728-C4092ECE-ACE0-4A27-B949-2C80261355E0Q38847841-591CEBE6-ADC8-436E-AC75-F42C93275A7AQ39865674-9726C06D-92B1-4680-B8EF-D6E8C6C37333Q41200444-727D6081-D239-44F4-BC35-0C98FFE70165Q41814056-615DAC76-1B91-49EE-B0E0-BA093719BB31Q41862636-91733BD2-8E06-4AA7-BC32-78120B0962B7Q42351682-F743D6B2-BBF0-4331-8B81-3D4FB8D7F6F6Q45805141-74E5F1ED-E46F-482C-97F1-D4EAE9D6384FQ46091045-9631CEE7-0D4D-4987-B37F-4B42C83B8AD3Q47124626-A80AD1A2-9670-45E8-8B22-99FA72EFE3B9Q47172970-4255D94E-E592-432C-9850-A079B9DE4977Q47877881-1C74E29A-5749-4CE5-B15D-9444084CA9D0Q47968881-4047F049-A7A9-43BD-B3CE-AF3439705DA5Q50919144-FC6069EB-7944-4BBC-A233-F2A1AA8976FB
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Busulfan in hematopoietic stem cell transplantation
@ast
Busulfan in hematopoietic stem cell transplantation
@en
Busulfan in hematopoietic stem cell transplantation
@nl
type
label
Busulfan in hematopoietic stem cell transplantation
@ast
Busulfan in hematopoietic stem cell transplantation
@en
Busulfan in hematopoietic stem cell transplantation
@nl
prefLabel
Busulfan in hematopoietic stem cell transplantation
@ast
Busulfan in hematopoietic stem cell transplantation
@en
Busulfan in hematopoietic stem cell transplantation
@nl
P2860
P1476
Busulfan in hematopoietic stem cell transplantation
@en
P2093
Borje S Andersson
Stefan O Ciurea
P2860
P304
P356
10.1016/J.BBMT.2008.12.489
P577
2009-02-12T00:00:00Z